[ad_1]
LONDON July 18, 2018 / PRNewswire / – In the last 50 years, the field of nuclear medicine has shown a close link between investment in chemistry and the development of radionuclides and radionuclides.
Download the full report: https://www.reportbuyer.com/product/3716553
Nuclear medicine includes diagnostic and therapeutic techniques that use radioisotopes for applications such as oncology, cardiovascular diseases and cardiovascular diseases. neurological disorders to provide information at the molecular and cellular level to examine, monitor tissue function, study disease progression, and evaluate responses to treatment.
The world market for nuclear medicine will reach $ 9,367.8 million in 2024 average single-digit CAGR. Increased applications of radioisotopes, public awareness, the use of SPECT / CT and PET / CT scanners, the abundance of radiopharmaceuticals, the advancement of imaging technologies ( hybrid imaging) and the targeted treatment of alpha-therapies stimulate the growth of the nuclear medicine market. In addition, growing needs in emerging markets, the production of radiopharmaceuticals from cyclotrons, effective diagnostics and treatments, radioisotope radioisotopes and the replacement of old / traditional equipment are all opportunities that could stimulate the growth of the nuclear medicine market. classified on the basis of the diagnostic-therapeutic modality. The diagnostics market has held the largest market turnover in 2017 and is expected to grow at single digit CAGR due to the increase in SPECT and PET procedures. The Therapeutic Products segment is expected to be the fastest growing CAGR segment from 2017 to 2024 due to technological advancements in the targeted treatment of cancers. The potential new radioisotopes being developed and the advancement of neurological treatments are key factors in the growth of the therapeutic products market. Product diagnosis is segmented into SPECT and PET. The SPECT market held the largest market due to the increase in TC-99m isotope applications and product approvals. SPECT is segmented based on technetium (Tc-99m), thallium (Tl-201), gallium (Ga-67), iodine (I-123), samarium (Sm-153) isotopes, in yttrium ( Y-90 ), rhenium (Re-186) and others. Technetium (Tc-99m) accounted for the largest share in 2017 and represents the most dynamic market with single-digit CAGR growth from 2017 to 2024 due to increased Tc refrigeration kit approvals -99m for different applications. The SPECT application market is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for the largest share in 2017 and remains the most dynamic market due to the increase in the number of cases of cardiac imaging using Tc-99m.
PET is the fastest growing segment of the CAGR from 2017 to 2024 cyclotron for the production of PET isotopes increasing its availability. PET isotopes include fluorodeoxyglucose (18F-FDG), gallium (Ga-68), rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2017 and remains the fastest growing market from 2017 to 2024 due to the increase in applications related to neurology, bone scintigraphy, the 39, infection and inflammation. Applications PET is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for the largest share in 2017 and is the fastest growing market between 2017 and 2024, due to the increase in the number of patients with lung cancer, cancer of the thyroid and breast cancer
. on the type of radiation in alpha radiation, beta radiation and brachytherapy. Alpha radiation accounted for the largest share in 2017 and is the fastest growing market with a double-digit CAGR from 2017 to 2024 due to the new approval of Ra-223 refrigerant kits by the FDA and other regulatory bodies. Beta isotope radiotherapy is segmented in Y-90 I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. I-131 held the largest share and is expected to grow at the CAGR from 2017 to 2024 due to increased use in the treatment of thyroid cancer cases. The Lu-177 segment experienced the fastest growth at the single-digit CAGR from 2017 to 2024 due to the increased approval of Lu-177-based radiopharmaceuticals for the treatment of cancer. neuroendocrine tumor. The brachytherapy isotopes are segmented into I-125, Cs-131, Ir-192, Pd-103 and others. The I-125 market represents the largest share in 2017 and the most dynamic market with a projected CAGR of 3.7% from 2017 to 2024 due to the increase in the use of I-125 treatment. lung cancer, prostate cancer and ocular diseases (retinoblastoma and ocular plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastroenteropancreatic-neuroendocrine tumor, metastatic bone cancer, breast cancer and others. The prostate cancer market accounted for the largest share in 2017 and is the fastest growing market with double-digit CAGR growth from 2017 to 2024 due to increased use of cancer treatment of the prostate
hospitals, outpatient centers, diagnostic centers and others. The hospital accounted for the largest share in 2017 and is the fastest growing market with a CAGR of 7.2% between 2017 and 2024 due to availability of cyclotrons for isotope production and the use of advanced hybrid imaging
to reach $ 256.9 million by 2024. The market for nuclear medicine includes stable isotopes that are classified into isotopes and applications. The isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), sulfur (S-32) and d & # 39; 39; others. Deuterium (D-2) accounted for the largest share in 2017 and the fastest-growing market with CAGR growth at a low level from 2017 to 2024 due to the use of deuterium as a dietary supplement. Water depleted in deuterium. the patient through the anticancer effect and modification of deuterium leads to the development of new highly differentiated drugs that have therapeutic applications in diabetic nephropathy, hot flushes, spasticity, neuropathic pain and multiple melanoma. The market for stable isotope applications is segmented into diagnostic-therapy, pharmaceutical companies and others. The diagnostic-therapeutic market has achieved the largest market turnover of the market in 2017 and is expected to grow at a CAGR of 2.6% due to its use in the diagnosis and treatment of the pancreas, liver and skin cancers. intestinal disorders. Pharmaceuticals are expected to be the fastest growing segment from 2017 to 2024 due to new developments in the use of stable isotopes involving biopolymers, where isotopically labeled species are generated from cells grown on growth media. ] North America is the largest market, with a significant share followed by Europe Asia-Pacific and Rest of the World. The North American region dominated the largest revenue market and is expected to grow at a single-digit CAGR. The increasing use of SPECT and PET scanners, technological advances in equipment, the increased use of fusion imaging, targeted cancer treatment based on alpha radioimmunotherapy and the complete availability of radiopharmaceuticals has led to market growth in this region. However, the Asia-Pacific region is expected to experience a high average annual growth rate from 2017 to 2024 due to increased public awareness and enforcement.
The global market for nuclear medicine is a competitive market. existing players in this market are involved in the development of new and advanced products to maintain their market share and also acquire small businesses for the expansion of their products. Some of the main players in the nuclear medicine market are Curium Pharma ( France ), Bayer AG ( Germany ), GE Company (United States), Cardinal Health (United States) , Jubilant Life Science ( India ), Lantheus Medical Imaging (USA), Novartis International AG (Advanced Accelerator) ( Switzerland ), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) ( South Africa ), Siemens AG ( Germany ) and Fujifilm Holding Corporation ( Japan )
The report provides a detailed market analysis of the above-mentioned segments in the following regions:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)
Download the full report: https: //www.reportbuye r.com/product/3716553
About Reportbuyer
Reportbuyer is a leadi An industrial intelligence solution that provides all the market research reports of the best publishers
For more d & # 39, information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
http://www.reportbuyer.com
Source link
